Applied BioCode (6598.TW) Dionica Cijena
Applied BioCode Cijena
Revenue has compounded at 27,1% per year over the past 12 years to 475,20 mil. TWD. Applied BioCode's net margin stands at −42,3%, up from −51,6% several years earlier. The stock trades about 44% above its 52-week low.
Cijena dionice Applied BioCode
Detalji
Tečaj
ⓘPregled
Dijagram cijene dionica pruža detaljan i dinamičan uvid u performanse Applied BioCode-dionice te prikazuje agregirane cijene na dnevnoj, tjednoj ili mjesečnoj razini. Korisnici mogu mijenjati različite vremenske okvire kako bi pažljivo analizirali povijest dionice i donijeli informirane odluke o investiranju.
Intraday Funkcija
Intraday funkcija pruža podatke u stvarnom vremenu i omogućava investitorima praćenje fluktuacija cijene Applied BioCode-dionice tijekom trgovačkog dana kako bi donosili pravovremene i strateške odluke o ulaganju.
Ukupni povrat i relativna promjena cijene
Pogledajte ukupni povrat Applied BioCode-dionice kako biste procijenili njezinu profitabilnost tijekom vremena. Relativna promjena cijene, temeljena na prvoj dostupnoj cijeni u odabranom vremenskom okviru, pruža uvid u performanse dionice i pomaže u procjeni njezinog potencijala za ulaganje.
Interpretacija i ulaganje
Iskoristite opsežne podatke prikazane na dijagramu cijene dionica za analizu tržišnih trendova, kretanja cijena i potencijalnih povrata od Applied BioCode. Donosite informirane odluke o ulaganju uspoređujući različite vremenske okvire i vrednujući intraday podatke za optimizirano upravljanje portfeljem.
| Datum | Applied BioCode Cijena dionice |
|---|---|
| 13. 08. 2026. | 27,75 TWD |
| 12. 08. 2026. | 27,80 TWD |
| 11. 08. 2026. | 27,65 TWD |
| 10. 08. 2026. | 28,80 TWD |
| 07. 08. 2026. | 28,80 TWD |
| 06. 08. 2026. | 30,15 TWD |
| 05. 08. 2026. | 31,10 TWD |
| 04. 08. 2026. | 31,50 TWD |
| 03. 08. 2026. | 31,00 TWD |
| 31. 07. 2026. | 30,20 TWD |
| 30. 07. 2026. | 28,75 TWD |
| 29. 07. 2026. | 29,85 TWD |
| 28. 07. 2026. | 29,10 TWD |
| 27. 07. 2026. | 30,00 TWD |
| 24. 07. 2026. | 27,70 TWD |
| 23. 07. 2026. | 28,80 TWD |
| 22. 07. 2026. | 27,85 TWD |
| 21. 07. 2026. | 26,65 TWD |
| 20. 07. 2026. | 26,85 TWD |
| 17. 07. 2026. | 27,65 TWD |
| 16. 07. 2026. | 25,20 TWD |
| 15. 07. 2026. | 26,15 TWD |
| 14. 07. 2026. | 23,80 TWD |
| 13. 07. 2026. | 24,80 TWD |
| 10. 07. 2026. | 22,85 TWD |
| 09. 07. 2026. | 22,85 TWD |
| 08. 07. 2026. | 22,75 TWD |
| 07. 07. 2026. | 22,95 TWD |
| 06. 07. 2026. | 23,25 TWD |
| 03. 07. 2026. | 23,05 TWD |
| 02. 07. 2026. | 22,75 TWD |
| 01. 07. 2026. | 22,50 TWD |
| 30. 06. 2026. | 22,85 TWD |
| 29. 06. 2026. | 22,85 TWD |
| 26. 06. 2026. | 22,80 TWD |
| 25. 06. 2026. | 22,90 TWD |
| 24. 06. 2026. | 23,20 TWD |
| 23. 06. 2026. | 23,45 TWD |
| 22. 06. 2026. | 23,75 TWD |
| 18. 06. 2026. | 24,15 TWD |
| 17. 06. 2026. | 24,40 TWD |
| 16. 06. 2026. | 24,40 TWD |
| 15. 06. 2026. | 25,00 TWD |
| 12. 06. 2026. | 24,60 TWD |
| 11. 06. 2026. | 24,50 TWD |
| 10. 06. 2026. | 24,90 TWD |
| 09. 06. 2026. | 25,00 TWD |
| 08. 06. 2026. | 24,50 TWD |
| 05. 06. 2026. | 24,50 TWD |
| 04. 06. 2026. | 24,50 TWD |
| 03. 06. 2026. | 24,10 TWD |
| 02. 06. 2026. | 24,30 TWD |
| 01. 06. 2026. | 24,20 TWD |
| 29. 05. 2026. | 24,75 TWD |
| 28. 05. 2026. | 24,75 TWD |
| 27. 05. 2026. | 24,95 TWD |
| 26. 05. 2026. | 24,85 TWD |
| 25. 05. 2026. | 24,50 TWD |
| 22. 05. 2026. | 24,30 TWD |
| 21. 05. 2026. | 24,30 TWD |
| 20. 05. 2026. | 24,20 TWD |
| 19. 05. 2026. | 24,65 TWD |
| 18. 05. 2026. | 24,50 TWD |
| 15. 05. 2026. | 24,35 TWD |
| 14. 05. 2026. | 23,75 TWD |
| 13. 05. 2026. | 24,15 TWD |
| 12. 05. 2026. | 23,35 TWD |
| 11. 05. 2026. | 22,70 TWD |
| 08. 05. 2026. | 22,50 TWD |
| 07. 05. 2026. | 22,60 TWD |
| 06. 05. 2026. | 22,90 TWD |
| 05. 05. 2026. | 22,55 TWD |
| 04. 05. 2026. | 22,55 TWD |
| 30. 04. 2026. | 21,45 TWD |
| 29. 04. 2026. | 21,95 TWD |
| 28. 04. 2026. | 21,90 TWD |
| 27. 04. 2026. | 21,90 TWD |
| 24. 04. 2026. | 21,95 TWD |
| 23. 04. 2026. | 21,85 TWD |
| 22. 04. 2026. | 22,15 TWD |
| 21. 04. 2026. | 22,25 TWD |
| 20. 04. 2026. | 22,70 TWD |
| 17. 04. 2026. | 22,80 TWD |
| 16. 04. 2026. | 22,90 TWD |
| 15. 04. 2026. | 22,80 TWD |
| 14. 04. 2026. | 22,60 TWD |
| 13. 04. 2026. | 22,60 TWD |
| 10. 04. 2026. | 22,00 TWD |
| 09. 04. 2026. | 21,80 TWD |
| 08. 04. 2026. | 22,80 TWD |
| 07. 04. 2026. | 22,55 TWD |
| 02. 04. 2026. | 23,10 TWD |
| 01. 04. 2026. | 23,40 TWD |
| 31. 03. 2026. | 22,65 TWD |
| 30. 03. 2026. | 23,30 TWD |
| 27. 03. 2026. | 23,35 TWD |
| 26. 03. 2026. | 23,55 TWD |
| 25. 03. 2026. | 24,15 TWD |
| 24. 03. 2026. | 23,65 TWD |
| 23. 03. 2026. | 24,25 TWD |
| 20. 03. 2026. | 24,95 TWD |
| 19. 03. 2026. | 25,00 TWD |
| 18. 03. 2026. | 24,80 TWD |
| 17. 03. 2026. | 24,60 TWD |
| 16. 03. 2026. | 24,80 TWD |
| 13. 03. 2026. | 25,05 TWD |
| 12. 03. 2026. | 24,55 TWD |
| 11. 03. 2026. | 25,30 TWD |
| 10. 03. 2026. | 23,90 TWD |
| 09. 03. 2026. | 23,60 TWD |
| 06. 03. 2026. | 24,65 TWD |
| 05. 03. 2026. | 24,50 TWD |
| 26. 02. 2026. | 25,30 TWD |
| 25. 02. 2026. | 24,55 TWD |
| 24. 02. 2026. | 24,35 TWD |
| 23. 02. 2026. | 24,50 TWD |
| 11. 02. 2026. | 24,05 TWD |
| 10. 02. 2026. | 24,05 TWD |
| 09. 02. 2026. | 25,65 TWD |
| 06. 02. 2026. | 23,35 TWD |
| 05. 02. 2026. | 24,30 TWD |
| 04. 02. 2026. | 24,40 TWD |
| 03. 02. 2026. | 24,10 TWD |
| 02. 02. 2026. | 23,60 TWD |
| 30. 01. 2026. | 24,10 TWD |
| 29. 01. 2026. | 24,05 TWD |
| 28. 01. 2026. | 24,80 TWD |
| 27. 01. 2026. | 24,15 TWD |
| 26. 01. 2026. | 23,95 TWD |
| 23. 01. 2026. | 23,60 TWD |
| 22. 01. 2026. | 24,05 TWD |
| 21. 01. 2026. | 23,45 TWD |
| 20. 01. 2026. | 23,90 TWD |
| 19. 01. 2026. | 24,50 TWD |
| 16. 01. 2026. | 24,45 TWD |
| 15. 01. 2026. | 24,60 TWD |
| 13. 01. 2026. | 23,40 TWD |
| 12. 01. 2026. | 24,25 TWD |
| 09. 01. 2026. | 23,15 TWD |
| 08. 01. 2026. | 23,05 TWD |
| 07. 01. 2026. | 22,30 TWD |
| 06. 01. 2026. | 22,40 TWD |
| 05. 01. 2026. | 22,35 TWD |
| 02. 01. 2026. | 22,00 TWD |
| 31. 12. 2025. | 22,00 TWD |
| 30. 12. 2025. | 22,00 TWD |
| 29. 12. 2025. | 22,30 TWD |
| 26. 12. 2025. | 22,05 TWD |
| 24. 12. 2025. | 21,60 TWD |
| 23. 12. 2025. | 22,00 TWD |
| 22. 12. 2025. | 22,10 TWD |
| 19. 12. 2025. | 21,50 TWD |
| 18. 12. 2025. | 21,25 TWD |
| 17. 12. 2025. | 21,10 TWD |
| 16. 12. 2025. | 21,10 TWD |
| 15. 12. 2025. | 21,25 TWD |
| 12. 12. 2025. | 21,10 TWD |
| 11. 12. 2025. | 21,40 TWD |
| 10. 12. 2025. | 21,45 TWD |
| 09. 12. 2025. | 21,30 TWD |
| 08. 12. 2025. | 21,40 TWD |
| 05. 12. 2025. | 21,55 TWD |
| 04. 12. 2025. | 21,40 TWD |
| 03. 12. 2025. | 21,65 TWD |
| 02. 12. 2025. | 21,65 TWD |
| 01. 12. 2025. | 21,75 TWD |
| 28. 11. 2025. | 22,10 TWD |
| 27. 11. 2025. | 21,70 TWD |
| 26. 11. 2025. | 21,55 TWD |
| 25. 11. 2025. | 21,35 TWD |
| 24. 11. 2025. | 21,20 TWD |
| 21. 11. 2025. | 21,20 TWD |
| 20. 11. 2025. | 20,95 TWD |
| 19. 11. 2025. | 20,55 TWD |
| 18. 11. 2025. | 21,00 TWD |
| 17. 11. 2025. | 21,00 TWD |
| 14. 11. 2025. | 21,10 TWD |
| 13. 11. 2025. | 21,25 TWD |
| 12. 11. 2025. | 21,30 TWD |
| 11. 11. 2025. | 21,85 TWD |
| 10. 11. 2025. | 22,70 TWD |
| 07. 11. 2025. | 23,10 TWD |
| 06. 11. 2025. | 22,70 TWD |
| 05. 11. 2025. | 22,70 TWD |
| 04. 11. 2025. | 22,65 TWD |
| 03. 11. 2025. | 22,80 TWD |
| 31. 10. 2025. | 22,90 TWD |
| 30. 10. 2025. | 23,00 TWD |
| 29. 10. 2025. | 22,55 TWD |
| 28. 10. 2025. | 23,05 TWD |
| 27. 10. 2025. | 23,00 TWD |
| 23. 10. 2025. | 23,10 TWD |
| 22. 10. 2025. | 23,15 TWD |
| 21. 10. 2025. | 23,00 TWD |
| 20. 10. 2025. | 23,10 TWD |
| 17. 10. 2025. | 23,00 TWD |
| 16. 10. 2025. | 22,95 TWD |
| 15. 10. 2025. | 22,85 TWD |
| 14. 10. 2025. | 22,75 TWD |
| 13. 10. 2025. | 23,00 TWD |
| 09. 10. 2025. | 23,10 TWD |
| 08. 10. 2025. | 22,70 TWD |
| 07. 10. 2025. | 22,95 TWD |
| 03. 10. 2025. | 22,55 TWD |
| 02. 10. 2025. | 22,60 TWD |
| 01. 10. 2025. | 23,30 TWD |
| 30. 09. 2025. | 23,65 TWD |
| 26. 09. 2025. | 23,60 TWD |
| 25. 09. 2025. | 23,00 TWD |
| 24. 09. 2025. | 22,65 TWD |
| 23. 09. 2025. | 22,60 TWD |
| 22. 09. 2025. | 22,45 TWD |
| 19. 09. 2025. | 22,70 TWD |
| 18. 09. 2025. | 22,95 TWD |
| 17. 09. 2025. | 23,05 TWD |
| 16. 09. 2025. | 23,10 TWD |
| 15. 09. 2025. | 23,05 TWD |
| 12. 09. 2025. | 23,15 TWD |
| 11. 09. 2025. | 23,35 TWD |
| 10. 09. 2025. | 23,35 TWD |
| 09. 09. 2025. | 23,25 TWD |
| 08. 09. 2025. | 21,40 TWD |
| 05. 09. 2025. | 20,85 TWD |
| 04. 09. 2025. | 22,00 TWD |
| 03. 09. 2025. | 20,60 TWD |
| 02. 09. 2025. | 19,70 TWD |
| 01. 09. 2025. | 19,35 TWD |
| 29. 08. 2025. | 19,60 TWD |
| 28. 08. 2025. | 19,55 TWD |
| 27. 08. 2025. | 19,55 TWD |
| 26. 08. 2025. | 19,55 TWD |
| 25. 08. 2025. | 19,60 TWD |
| 22. 08. 2025. | 19,35 TWD |
| 21. 08. 2025. | 19,35 TWD |
| 20. 08. 2025. | 19,25 TWD |
| 19. 08. 2025. | 19,30 TWD |
| 18. 08. 2025. | 19,55 TWD |
| 15. 08. 2025. | 19,55 TWD |
Applied BioCode dionica promet, EBIT, dobit
3 godine
5 godina
10 godina
25 godina
Max
Details
Applied BioCode Dionice Ključni pokazatelji
| PRIHODmil. TWD |
|---|
| Rast prihoda% |
| BRUTO MARGINA% |
| BRUTO DOHODAKmil. TWD |
| EBITmil. TWD |
| EBIT-MARŽA% |
| DOBITmil. TWD |
| Rast dobiti% |
| BROJ DIONICAmil. |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26,00 | 15,00 | 23,00 | 11,00 | 26,00 | 37,00 | 104,00 | 299,00 | 319,00 | 390,00 | 395,00 | 343,00 | 475,00 | – |
| – | −42,31 | 53,33 | −52,17 | 136,36 | 42,31 | 181,08 | 187,50 | 6,69 | 22,26 | 1,28 | −13,16 | 38,48 | – |
| 7,69 | 13,33 | 26,09 | 36,36 | 30,77 | 43,24 | 50,00 | 64,55 | 59,25 | 60,00 | 67,85 | 59,18 | 54,74 | – |
| 2,00 | 2,00 | 6,00 | 4,00 | 8,00 | 16,00 | 52,00 | 193,00 | 189,00 | 234,00 | 268,00 | 203,00 | 260,00 | 260,00 |
| −83,00 | −162,00 | −221,00 | −194,00 | −263,00 | −267,00 | −273,00 | −99,00 | −162,00 | −181,00 | −186,00 | −277,00 | −223,00 | – |
| −319,23 | −1.080,00 | −960,87 | −1.763,64 | −1.011,54 | −721,62 | −262,50 | −33,11 | −50,78 | −46,41 | −47,09 | −80,76 | −46,95 | – |
| −208,00 | −71,00 | −21,00 | −135,00 | −263,00 | −268,00 | −280,00 | −103,00 | −165,00 | −184,00 | −164,00 | −260,00 | −201,00 | – |
| – | −65,87 | −70,42 | 542,86 | 94,81 | 1,90 | 4,48 | −63,21 | 60,19 | 11,52 | −10,87 | 58,54 | −22,69 | – |
| 102,65 | 102,65 | 102,65 | 40,05 | 46,66 | 59,42 | 71,16 | 81,59 | 81,73 | 81,69 | 81,77 | 102,79 | 102,65 | 102,65 |
Detalji
GuV
ⓘPrihod i rast
Prihod tvrtke Applied BioCode i rast prihoda ključni su za razumijevanje financijskog zdravlja i operativne učinkovitosti poduzeća. Stalni porast prihoda ukazuje na sposobnost poduzeća da učinkovito tržišno pozicionira i prodaje svoje proizvode ili usluge, dok postotak rasta prihoda pruža uvid u tempo kojim poduzeće raste tijekom godina.
Bruto marža
Bruto marža ključan je faktor koji pokazuje postotak prihoda iznad troškova proizvodnje. Viša bruto marža ukazuje na učinkovitost poduzeća u kontroli proizvodnih troškova i obećava potencijalnu profitabilnost i financijsku stabilnost.
EBIT i EBIT marža
EBIT (Earnings Before Interest and Taxes) i EBIT marža pružaju duboke uvide u profitabilnost poduzeća, bez utjecaja kamata i poreza. Investitori često ocjenjuju ove metrike kako bi procijenili operativnu učinkovitost i inherentnu profitabilnost poduzeća neovisno o njegovoj financijskoj strukturi i poreznoj okolini.
Dohodak i rast
Neto dohodak i njegov kasniji rast neophodni su za investitore koji žele razumjeti profitabilnost poduzeća. Stalni rast dohotka ističe sposobnost poduzeća da poveća svoju profitabilnost tijekom vremena te odražava operativnu učinkovitost, stratešku konkurentnost i financijsko zdravlje.
Izdane dionice
Izdane dionice odnose se na ukupni broj dionica koje je poduzeće izdalo. To je ključno za izračun važnih pokazatelja poput zarade po dionici (EPS), koji je za investitore od ključne važnosti za procjenu profitabilnosti poduzeća po osnovi po dionici i pruža detaljniji pregled financijskog zdravlja i vrednovanja.
Interpretacija godišnjeg uspoređivanja
Uspoređivanje godišnjih podataka omogućuje investitorima da identificiraju trendove, procijene rast poduzeća i predviđaju potencijalnu buduću izvedbu. Analiza kako se pokazatelji poput prihoda, dohotka i marži mijenjaju iz godine u godinu može pružiti vrijedne uvide u operativnu učinkovitost, konkurentnost i financijsko zdravlje poduzeća.
Očekivanja i prognoze
Investitori često uspoređuju trenutne i prošle financijske podatke s tržišnim očekivanjima. Ta usporedba pomaže u procjeni da li poduzeće Applied BioCode posluje kako se očekivalo, ispod prosjeka ili iznad prosjeka te pruža ključne podatke za investicijske odluke.
Applied BioCode Aktie marže
3 godine
5 godina
10 godina
25 godina
Max
Details
Applied BioCode dionica prihod, EBIT, dobit po dionici
3 godine
5 godina
10 godina
25 godina
Max
Details
Dioncia Applied BioCode i analiza dionice
Vrednovanje Applied BioCode prema fer vrijednosti
Detalji
Fair Value
ⓘRazumijevanje Fair Value
Fair Value dionice pruža uvide u to je li dionica trenutno podcijenjena ili precijenjena. Izračunava se na temelju dobiti, prihoda ili dividende i pruža sveobuhvatan pogled na unutarnju vrijednost dionice.
Fair Value baziran na dobiti
Ovaj se izračunava množenjem dobiti po dionici sa prosječnim P/E omjerom proteklih odabranih godina za izračunavanje prosječne vrijednosti (glättung). Ako je Fair Value viši od trenutne tržišne cijene, to ukazuje na to da je dionica podcijenjena.
Primjer 2022
Fair Value Dobit 2022 = Dobit po dionici 2022 / Prosječni P/E omjer 2019 - 2021 (glättung 3 godine)
Fair Value baziran na prihodima
Izračunava se množenjem prihoda po dionici sa prosječnim omjerom cijene i prihoda proteklih odabranih godina za izračun prosječnih vrijednosti (glättung). Dionica se smatra podcijenjenom ako Fair Value premašuje tekuću cijenu dionice.
Primjer 2022
Fair Value Prihod 2022 = Prihod po dionici 2022 / Prosječni omjer cijene i prihoda 2019 - 2021 (glättung 3 godine)
Fair Value baziran na dividendi
Ova vrijednost se određuje dijeljenjem dividende po dionici s prosječnim prinosom dividende odabranih proteklih godina za izračun prosječnih vrijednosti (glättung). Veći Fair Value u odnosu na tržišnu cijenu signalizira da je dionica podcijenjena.
Primjer 2022
Fair Value Dividenda 2022 = Dividenda po dionici 2022 * Prosječni prinos dividende 2019 - 2021 (glättung 3 godine)
Očekivanja i prognoze
Buduća očekivanja daju potencijalne trajektorije za kretanje cijena dionica i pomažu investitorima u donošenju odluka. Očekivane vrijednosti su prognozirani brojevi Fair Value, uzimajući u obzir trendove rasta ili pada dobiti, prihoda ili dividende.
Usporedna analiza
Usporedba Fair Value, na osnovi dobiti, prihoda i dividendi, pruža sveobuhvatan pregled financijskog zdravlja dionice. Praćenje godišnjih i po-godišnjih varijacija pridonosi razumijevanju stalnosti i pouzdanosti performansi dionice.
Vrednovanje Applied BioCode prema historijskom KGV-u, EBIT-multiplom i KUV-u
Applied BioCode dionica, godišnji prinos
Detalji
Rendita
ⓘRazumijevanje grafikona prinosa
Grafikon prinosa pruža sveobuhvatan pregled godišnjeg prinosa za . Podijeljen je u dva dijela - prinos od cijene dionice i prinos od dividendi te pruža uvid u ukupnu učinkovitost i profitabilnost investicije.
Prinos od cijene dionice
Ovaj odjeljak prikazuje godišnji prinos koji proizlazi iz povećanja ili smanjenja cijene dionica . Analiza ovih podataka može pomoći investitorima da razumiju povijesnu izvedbu dionice i predviđaju buduće trendove.
Prinos od dividendi
Prinos od dividendi pokazuje postotak prinosa iz dividendi koje isplaćuje . To je ključni pokazatelj za investitore koji žele ostvariti zaradu pored povećanja vrijednosti dionice.
Donošenje odluka o investiranju
Procjenom i prinosa od cijene dionice i prinosa od dividendi, investitori mogu steći uvid u ukupni povrat investicije. To pomaže u donošenju informiranih odluka i uravnoteženju između strategija ulaganja usmjerenih na rast i prihod.
Applied BioCode Broj dionica
3 godine
5 godina
10 godina
25 godina
Max
Details
Struktura dioničara Applied BioCode
| % | Ime |
|---|---|
9,73018% | |
9,16736% | |
3,94085% | |
3,06682% | |
3,01164% | |
2,48303% |
Applied BioCode Beneficial Ownership Filings (SEC 13D/G)
Applied BioCode Uprava i nadzorni odbor
14 members · 0 % women
Management
Mr. Zohn-Zen Ho
Founder, Chief Technology Officer, General Manager, Director · od 2008
Mr. Liang-Kai Huang
Chief Financial Officer, Corporate Governance Officer
Mr. Michael Aye
Vice President-Molecular Products
Mr. Donald Wong
Vice President-Productions
Mr. Youning Chen
Deputy General Manager-Taiwan Sub-Subsidiary
Gerald Kowalski
Deputy General Manager-Operation
Board of Directors
Mr. Jia-Long Lee
Chairman of the Board · od 2016
Mr. Benjamin Jen
Director
Lizzie Lee
Director
Mr. Wen-Jing Tsai
Independent Director
James Tsu
Independent Director
Jim Wu
Independent Director
Često postavljana pitanja o dionici Applied BioCode
The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.
Applied BioCode Corp is primarily active in the biotechnology industry.
The main competitors of Applied BioCode Corp in the market include companies such as Illumina, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, and QIAGEN.
Applied BioCode Corp is a leading biotechnology company specializing in developing and commercializing molecular diagnostic systems. Founded in [insert year], Applied BioCode Corp has a rich history in the field of biotech and has consistently delivered innovative solutions for healthcare professionals. The company is dedicated to improving patient care by revolutionizing diagnostic testing through its proprietary barcoded magnetic bead technology. With a team of highly skilled scientists and engineers, Applied BioCode Corp has gained recognition for its advanced diagnostic platforms that offer high throughput, multiplex capability, and cost-effectiveness. The company continues to expand its product portfolio and collaborate with industry partners to address the evolving needs of the healthcare industry.
Applied BioCode Corp has achieved several significant milestones in its journey. The company has made strides in the development and commercialization of its proprietary Barcoded Magnetic Bead (BMB) technology. This innovative technology offers multiplex testing capabilities, enabling simultaneous analysis of multiple targets, including genes, proteins, and pathogens. Applied BioCode Corp has successfully launched its FDA-cleared BioCode MDx 3000 system, which allows complex diagnostic testing with high precision and speed. Additionally, the company has secured strategic partnerships and collaborations with major healthcare institutions, facilitating the adoption of its BMB technology. Through these achievements, Applied BioCode Corp has established itself as a leader in the field of molecular diagnostics.
Applied BioCode Corp is primarily present in the United States, particularly in the state of California.
Applied BioCode Corp is a prominent biotechnology company that values innovation, integrity, and excellence. With a strong corporate philosophy, Applied BioCode Corp focuses on developing cutting-edge technologies and solutions to revolutionize diagnostics and improve patient care. By merging the fields of molecular diagnostics and multiplex biomarker detection, the company aims to address unmet clinical needs. Applied BioCode Corp is committed to providing accurate and efficient diagnostic products that empower healthcare professionals and ultimately enhance patient outcomes. With its forward-thinking approach and commitment to quality, Applied BioCode Corp strives to contribute to the advancement of healthcare and improve global health outcomes.
9 analysts currently rate the Applied BioCode stock: 0 recommend buying, 3 holding and 6 selling.
Converted at the current exchange rate, the Applied BioCode share trades at 0,75 EUR (27,75 TWD).
Applied BioCode Corp is a leading company in the field of molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable complex biochemical analysis with high accuracy, reliability, and throughput capacity. The business model of Applied BioCode Corp is based on the development and commercialization of diagnostic systems and products for food and water analysis, clinical diagnostics, and research. The company offers innovative solutions to meet the needs of customers in various industries. Applied BioCode Corp's main division is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal tract infections by simultaneously analyzing multiple samples for different bacteria, viruses, and parasites. Another product of the company is the BioCode Respiratory Pathogen Panel (RPP) system, which enables rapid and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP provides an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also produces labeling products such as BioCode screening platforms to enable customers to accurately and timely identify pathogens. The company also offers a wide range of sampling methods and accessories to meet the requirements of diverse customers and applications. Applied BioCode Corp's products are distributed worldwide and are used in various industries, such as food and water analysis, clinical diagnostics, and research. The company focuses on offering innovative solutions to its customers to help meet their needs in terms of analysis, diagnosis, and results. Applied BioCode Corp also operates partnerships and collaborations with other companies to introduce and further develop its systems and products in new areas. The company is constantly striving to improve the quality and accuracy of its products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a company that specializes in the development and commercialization of innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. It offers its customers accurate and reliable solutions to meet their requirements and enhance their efficiency. With an advanced product portfolio, global trade partners, and a dedicated team of professionals, Applied BioCode Corp is undoubtedly one of the leading companies in the field of molecular diagnostics. Applied BioCode Corp is a leading company specializing in molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable highly accurate, reliable, and high-throughput complex biochemical analyses. Their business model focuses on developing and marketing diagnostic systems and products for food and water analysis, clinical diagnostics, and research. They offer innovative solutions to meet the needs of customers in various industries. One of their main divisions is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal infections by simultaneously analyzing multiple samples for various bacteria, viruses, and parasites. Another product is the BioCode Respiratory Pathogen Panel (RPP) system, providing fast and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP offers an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also manufactures labeling products such as BioCode screening platforms, allowing for precise and timely identification of pathogens. They also offer a wide range of sampling methods and accessories to fulfill the requirements of different customers and applications. Their products are distributed worldwide and utilized in various industries including food and water analysis, clinical diagnostics, and research. The company focuses on providing customers with innovative solutions to fulfill their analytical, diagnostic, and result-related needs. They also engage in partnerships and collaborations with other companies to introduce and advance their systems and products in new areas. Applied BioCode Corp is committed to continuously improving the quality and accuracy of their products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a specialized company that develops and markets innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. Their accurate and reliable solutions help customers meet their requirements and increase efficiency. With their advanced product portfolio, global trade partnerships, and dedicated professional team, Applied BioCode Corp is a leading company in the field of molecular diagnostics.
Prihod za Applied BioCode trenutno se ne može izračunati.
Dobit za Applied BioCode trenutno se ne može izračunati.
KGV se za Applied BioCode trenutno ne može izračunati.
KUV se za Applied BioCode trenutno ne može izračunati.
Eulpool Quality Score za Applied BioCode je 4/10.
ISIN od Applied BioCode je KYG0488D1051. ISIN (International Securities Identification Number) je globalno jedinstvena identifikacija za vrijednosne papire.
Ticker od Applied BioCode je 6598.TW. Simbol tickera koristi se za trgovanje dionicama Applied BioCode na burzi.
Applied BioCode je isplaćivao dividende svake godine u proteklih 0 godina.
Applied BioCode je dodijeljen sektoru 'Zdravstvo'.
Dividende od Applied BioCode distribuiraju se u TWD.
Applied BioCode dionica
Applied BioCode Grupa usporediva
Applied BioCode Simbol
Applied BioCode FIGI
Sve temeljne informacije i detaljnu analizu Applied BioCode u detaljnom pregledu
Naša analiza dionica Applied BioCode uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Applied BioCode. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: